

**Reference: FOI.ICB-2526/255**

**Subject: Prescribing of Weight Loss Medicines**

*I can confirm that the ICB does hold some of the information requested; please see responses below:*

QUESTION	RESPONSE																																																		
<p>1. The <b>total number of prescriptions</b> for the following medicines where the drug was prescribed for weight loss or weight management:</p> <ul style="list-style-type: none"><li>○ Saxenda (liraglutide)</li><li>○ Wegovy (semaglutide)</li><li>○ Mounjaro (tirzepatide)</li></ul> <p>a. Please provide totals for each individual medicine, as well as an overall total for all medicines combined.</p> <p>b. Please provide this information for each year available, up to and including the most recent 12-month period.</p> <p>c. Please break down the data by setting, indicating whether prescriptions were issued by hospital-based specialist weight management services, GPs or community pharmacies.</p>	<table><tr><td>Calendar year</td><td>2017</td><td>2018</td><td>2019</td><td>2020</td><td>2021</td><td>2022</td><td>2023</td><td>2024</td><td>2025</td></tr><tr><td>Saxenda</td><td>3</td><td>15</td><td>6</td><td>8</td><td>49</td><td>78</td><td>95</td><td>6</td><td>1</td></tr><tr><td>Wegovy</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>13</td><td>161</td><td>56</td></tr><tr><td>Tirzepatide</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>388</td></tr><tr><td>Total</td><td>4</td><td>15</td><td>6</td><td>8</td><td>49</td><td>78</td><td>108</td><td>167</td><td>445</td></tr></table> <p>Above data is GP prescribing data and is the number of NHS prescriptions issued in general practice per calendar year. 2025 is up to 6/11/25. Saxenda and Wegovy prescribing is assumed for weight loss. Tirzepatide is count of prescriptions for patients with the codes of 'NHS obesity medication pathway started' since the date that code was added.</p> <p>Question 1 a and b – see table and comments above</p> <p>Question 1 Part c – Unable to provide break down at this level as secondary care/ other provider data not held, so data just relates to primary care (GP practice) prescribing.</p>	Calendar year	2017	2018	2019	2020	2021	2022	2023	2024	2025	Saxenda	3	15	6	8	49	78	95	6	1	Wegovy	1	0	0	0	0	0	13	161	56	Tirzepatide	0	0	0	0	0	0	0	0	388	Total	4	15	6	8	49	78	108	167	445
Calendar year	2017	2018	2019	2020	2021	2022	2023	2024	2025																																										
Saxenda	3	15	6	8	49	78	95	6	1																																										
Wegovy	1	0	0	0	0	0	13	161	56																																										
Tirzepatide	0	0	0	0	0	0	0	0	388																																										
Total	4	15	6	8	49	78	108	167	445																																										

2. In addition, please provide the total number of prescriptions for **Ozempic (semaglutide)** in your ICB area, **where weight loss was the intended use**, broken down by year and setting (as outlined above).

The ICB does not hold this data as the ICB does not hold patient level data. This drug is licensed for diabetes so assumptions around indication cannot be made.

*The information provided in this response is accurate as of 11 November 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.*